NCT03417817

Brief Summary

First introduced over 40 years ago, the 24-hour catheter-based pH studies have previously been found to be the gold standard in the diagnosis of gastro-oesophageal reflux disease (GORD). In 2003, the Bravo has revolutionised the study of GORD, allowing patients an improved comfort and ability to perform activities of daily living. The backflow of gastric acid (acid exposure) in the oesophagus is monitored by a tiny pH sensor located in a capsule which is pinned temporarily to the wall of the oesophagus at the time of endoscopy. Normal measurements for acid exposure are established for 48-hour studies. However, the investigators' studies have shown that extending the duration of recording to 96 hours further improved the diagnostic yield for GORD in patients with negative 24-hour catheter-based tests The 96-hour recording is the current standard of care, despite the lack of normal ranges for this duration of the recording. The basis for the diagnosis of GORD in 96-hours studies is based on the 48-hours normal controls. The objective of this study is to determine the normal values for oesophageal acid exposure using the wireless pH recording apparatus over 96 hours in asymptomatic healthy subjects with unrestricted activity and diet.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2018

Shorter than P25 for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 8, 2018

Completed
23 days until next milestone

First Posted

Study publicly available on registry

January 31, 2018

Completed
9 months until next milestone

Study Start

First participant enrolled

October 16, 2018

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2019

Completed
Last Updated

August 21, 2019

Status Verified

August 1, 2019

Enrollment Period

9 months

First QC Date

January 8, 2018

Last Update Submit

August 20, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Acid exposure time in 4 days/96 hours

    4 days

Secondary Outcomes (8)

  • Acid exposure time in 3 days/72 hours

    3 days

  • Percent total time pH < 4 for each 24-hour period

    1 day

  • Percent Upright time pH < 4 for each 24-hour period

    1 day

  • Percent Supine time pH < 4 for each 24-hour period

    1 day

  • Number of reflux episodes for each 24-hour period

    1 day

  • +3 more secondary outcomes

Study Arms (1)

Healthy subjects

OTHER

Bravo wireless pH monitoring over 96 hours

Device: Bravo

Interventions

BravoDEVICE

wireless pH monitoring over 96 hours

Healthy subjects

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Asymptomatic in:
  • GORD according to the Montreal GORD consensus definition
  • Dysphagia using the Hospital Odynophagia Dysphagia Questionnaire (HODQ) scoring \< 7
  • People without reflux referred for gastroscopy in context of other conditions e.g. iron deficiency anaemia, coeliac disease.
  • Subjects must sign an informed consent

You may not qualify if:

  • Gastro-oesophageal symptoms in accordance with Montreal criteria
  • Previous abdominal operations on GI tract
  • Antireflux treatments either prescribed or over the counter
  • BMI \> 35
  • History of hepatic diseases, oesophageal varices
  • History of ischemic heart disease, asthma
  • Anticoagulants
  • Allergies
  • Pregnancy
  • Any medical or non-medical condition that in the opinion of the research team will make the candidate unfit for this study e.g. drug abuse etc.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Guy's and St Thomas' NHS Foundation Trust

London, SE1 7EH, United Kingdom

Location

King's College London

London, WC2R 2LS, United Kingdom

Location

MeSH Terms

Conditions

Gastroesophageal Reflux

Condition Hierarchy (Ancestors)

Esophageal Motility DisordersDeglutition DisordersEsophageal DiseasesGastrointestinal DiseasesDigestive System Diseases

Study Officials

  • Terry Wong, MA MD

    Consultant Gastroenterologist, Guy's and St Thomas' NHS Foundation Trust

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Model Details: healthy subjects and subjects referred for gastroscopy in context of other conditions
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 8, 2018

First Posted

January 31, 2018

Study Start

October 16, 2018

Primary Completion

June 30, 2019

Study Completion

June 30, 2019

Last Updated

August 21, 2019

Record last verified: 2019-08

Data Sharing

IPD Sharing
Will not share

Locations